Psychedelic Policy Briefing: Week of June 16, 2026

Federal psychedelic policy in 2026 splits in two directions. Lawmakers and military officials are building clinical infrastructure for experimental therapeutics, while enforcement agencies freeze access and criminalize new compounds. The House Armed Services Committee is directing the Pentagon to investigate psilocybin pathways for service members, the VA is preparing for MDMA approvals, and Congress is codifying Trump's April executive order into law. Meanwhile, the DEA has stalled a three-year-old rescheduling petition and moved to emergency-ban a ketamine analog after only 52 law enforcement encounters. Veterans Affairs Secretary Doug Collins acknowledged the federal government has no ibogaine sourcing plan—and no budget for one. The result is a fragmented policy landscape where access and criminalization advance simultaneously, leaving patients and researchers in bureaucratic limbo. The post Psychedelic Policy Briefing: Week of June 16, 2026 appeared first on Psychedelics Today.